Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Adults using Kalydeco, Trikafta show lung function, nutrition gains

Adults using Kalydeco (ivacaftor) or Trikafta (ivacaftor/tezacaftor/elexacaftor) to treat their cystic fibrosis (CF) showed gains in lung function and nutritional status, according to a real-world, observational study in Australia. In contrast, no significant improvements in lung function were seen in adults or children with CF using Orkambi (ivacaftor/lumacaftor)…

Orkambi eased airway inflammation, boosted bacterial diversity

Treatment with Orkambi (lumacaftor/ivacaftor) for six months lessened airway inflammation and enhanced airway bacterial diversity in people with cystic fibrosis (CF), but only when administered before patients were chronically infected with the bacterium Pseudomonas aeruginosa, a study has found. The findings suggest that “CFTR modulators [such as Orkambi] should…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.